Arastradero Spółka z Ograniczoną Odpowiedzialnością (KRS 0000774124, NIP 7123383462) is a Polish company, headquartered in Warszawa, Mazowieckie voivodeship. ARASTRADERO operates in: Other research and experimental development on natural sciences and engineering (PKD 72.19.Z). Industry: Research and development. The company has been listed in the National Court Register since February 27, 2019.
Negative equity
Negative equity in 4 of 6 available reporting years.
No arrears identified in the analyzed sources
No arrears or bankruptcy proceedings identified in the analyzed sources.
Business profile - Arastradero
Identity
- Name
- Arastradero Spółka z Ograniczoną Odpowiedzialnością
- Legal form
- SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
- Founded
- February 27, 2019
- Registry status as of
- December 11, 2025
- Latest entry
- December 10, 2025
- Founding act
- 24.02.2019 R.
Articles of association history (3)
- February 24, 2019: 24.02.2019 R.
- February 14, 2020: 14.02.2020 R., REP. A NR 441/2020, NOTARIUSZ PAWEŁ MATUSIAK, KANCELARIA NOTARIALNA W WARSZAWIE, UCHYLENIE W CAŁOŚCI DOTYCHCZASOWEGO BRZMIANIA UMOWY SPÓŁKI ORAZ PRZYJĘCIE NOWEGO.
- April 2, 2024: 02.04.2024 R., REP. A NR 1688/2024, NOTARIUSZ AGNIESZKA SZCZEPANIK, KANCELARIA NOTARIALNA W LUBLINIE. ZMIANA UMOWY SPÓŁKI W § 22 UST. 5 I § 3 ORAZ UCHWALENIE NOWEGO TEKSTU JEDNOLITEGO UMOWY SPÓŁKI.
Activities
Main activity
72.19.ZOther research and experimental development on natural sciences and engineering
Other activities
Address and contact
- Address
- UL. PAŃSKA, 98, 104, 00-837, WARSZAWA, POLSKA
- Voivodeship
- MAZOWIECKIE
- District
- WARSZAWA
- Not disclosed in the registry
- Website
- Not disclosed in the registry
- E-delivery address
- Not disclosed in the registry
- Coordinates
- 52.2298, 21.0117approx.
Risk and payment profile - Arastradero
Credibility rating
23.2 / 100
Poor credibility
Insolvency risk
Moderate
Significant formal threat
Closure risk
32
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
Organizational stability signals
No instability signals - ownership, management, PKD codes and company name remain relatively stable.
Shareholder changes
1
1/7 yrs
Board changes
1
1/7 yrs
PKD changes
0
0/7 yrs
Name changes
0
0/7 yrs
Data from 7 years of registry activity.
Credibility history
Payment reliability score from 2019–2024
Current: E (23/100)
Trend: improving (+10.3 pts/year)
Bardzo słaba wiarygodność płatnicza – współpraca handlowa wiąże się z wysokim ryzykiem braku zapłaty.
Trade credit limit history
Standard limit from 2019–2024
Current: 603.51 PLN
Safe: 102.6 PLN
Operational status - Arastradero
Founded
February 27, 2019
7 years in operation
Legal form
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Registry: RejP
Headquarters
WARSZAWA
MAZOWIECKIE
Primary PKD
72.19.Z
Other research and experimental development on natural sciences and…
Share capital
11.2 K PLN
200 shares total
Shareholders
6
shareholders
Board
2 people
Filed years
6 years
2019–2024 · profitable: 1/6
Registry entries
22
latest: December 10, 2025
Risk signals
Revenue
N/A
2024
Net profit
3.4 K PLN
2024
Assets
69.0 K PLN
2024
Equity
-268.8 K PLN
2024
EBITDA
96.0 K PLN
2024
Valuation
51.3 K PLN
Low confidence
Low confidence
Companies in the same location
Public procurement
Trademarks
Reviews
Rate business credibility - Arastradero.
No ratings
Related articles
News
Bioceltix in the final EMA dialogue phase: BCX-CM-J could become Europe's first veterinary cell-therapy drug for dogs
Wrocław-based Bioceltix S.A. (KRS 0000744521) entered Q2 2026 in the final EMA dialogue phase regarding BCX-CM-J - Europe's first veterinary cell-therapy drug from mesenchymal stem cells for dogs with osteoarthritis. Responses to the final EMA questions are due in May 2026; the CVMP recommendation and marketing authorisation are possible in Q3/Q4 2026. Pre-commercial biotech: 2024 closed with a PLN 14.9 m loss on zero revenue; cash of PLN 33.6 m at year-end. Trigon DM maintained a buy rating with a price target of PLN 127.2.
News
Captor Therapeutics: PLN 36 m of cash at 30 September 2025, runway to mid-2026 - clinical data versus the cash clock
Wrocław-based Captor Therapeutics S.A. (KRS 0000756383) - a pre-commercial biotech specialising in TPD (Targeted Protein Degradation) - closed Q3 2025 with PLN 36 m of cash and grants securing financing to mid-2026. CT-01 (hepatocellular carcinoma) entered Phase I - the first patient dosed at Barcelona Clinic Liver Cancer. CT-03 (MCL-1 degrader) nearing clinical entry. Without a new R&D partnership or equity issuance in 2026, the company will need additional financing.
